Skip to content

Innovations in women's health care

Innovations in women's health care: a pilot study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-44cmcf5
Enrollment
Unknown
Registered
2025-11-06
Start date
2023-09-11
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer, breast cancer

Interventions

This is a quasi-experimental study. The study population is comprised of 1,217 female employees and dependents of Roche&apos
s employee health insurance plan. The study has only one arm: all female employees and dependents aged 25 to 74. The Sírio-Libanês Hospital Population Health team has a healthcare contract with Roche
s Healthcare program, which includes assistance from the Sírio-Libanês Population Health Digital Primary Care team, focusing on engagement in breast and cervical cancer screening. The study will analy
s impact. The study will be conducted throughout the entire period of care provided by the Sírio-Libanês Health Team to Roche employees and dependents. It should be noted that the healthcare program w
s effects will be analyzed by analyzing variables related to engagement, participant satisfaction, and self-rated health, considering the periods before and after the program&apos
s implementation. At the end of the study, data analysis, discussion, and publication will be conducted.

Sponsors

Sociedade Beneficente de Senhoras Hospital Sírio-Libanês
Lead Sponsor
Produtos Roche Químicos e Farmacêuticos S.A.
Collaborator

Eligibility

Sex/Gender
Female
Age
25 Years to 74 Years

Inclusion criteria

Inclusion criteria: All female employees, with a current employment contract and those dependent on the medical insurance of Roche employees within the age range of 25 to 74 years old will be invited to participate in this study; female

Exclusion criteria

Exclusion criteria: Women who are undergoing treatment for breast cancer or cervical cancer.

Design outcomes

Primary

MeasureTime frame
It is expected to achieve 100% adherence to the breast and cervical cancer screening program.

Secondary

MeasureTime frame
No secondary outcomes are expected.

Countries

Brazil

Contacts

Public ContactCamila Monteiro

Hospital Sirio-Libanês

camila.monteiro@hsl.org.br+55(11)980897909

Outcome results

None listed

Source: REBEC (via WHO ICTRP)